Background
Methods
Study design and setting
Sample size estimation and sampling technique
Data collection instrument and quality control
Data processing and analysis
Results
Socio-demographic characteristics of respondents
Variables | Category | Cases: N (%) | Controls: N (%) | p-value for Chi-square test |
---|---|---|---|---|
Age (years) | ≤35 | 119 (77.3) | 111 (72.1) | 0.295 |
>35 | 35 (22.7) | 43 (27.9) | ||
Sex | Male | 69 (44.8) | 71 (46.1) | 0.819 |
Female | 85 (55.2) | 83 (53.9) | ||
Marital status | Never married | 46 (29.9) | 37 (24) | 0.593 |
Married | 73 (47.4) | 81 (52.6) | ||
Separated | 6 (3.9) | 3 (2) | ||
Divorced | 18 (11.7) | 22 (14.3) | ||
Widowed | 11 (7.1) | 11 (7.1) | ||
Educational status | No education | 57 (37) | 55 (35.7) | 0.852 |
Primary | 59 (38.3) | 66 (42.9) | ||
Secondary | 28 (18.2) | 24 (15.6) | ||
Tertiary | 10 (6.5) | 9 (5.8) | ||
Occupational status | Farmer | 52 (33.8) | 47 (30.5) | 0.475 |
House Wife | 17 (11) | 19 (12.3) | ||
Student | 13 (8.4) | 11 (7.1) | ||
Merchant | 11 (7.1) | 9 (5.8) | ||
Employed | 24 (15.6) | 31 (20.1) | ||
Unemployed | 37 (24) | 37 (24) | ||
HIV serostatus disclosure | Yes | 107 (69.5) | 114 (74) | 0.376 |
No | 47 (30.5) | 40 (26) |
Clinical related characteristics of respondents
Variables | Category | Cases(n=154) | Controls (n=154) | p-value for Chi-square test |
---|---|---|---|---|
Frequency (%) | Frequency (%) | |||
Baseline body mass index (BMI ) | <16 | 14 (9.1) | 16 (10.4) | 0.349 |
16-18.5 | 44 (28.6) | 33 (21.4) | ||
>18.5 | 96 (62.3) | 105 (68.2) | ||
Current BMI | <16 | 27 (17.5) | 10 (6.5) | < 0.001 |
16-18.5 | 37 (24) | 12 (7.8) | ||
>18.5 | 90 (58.4) | 132 (85.7) | ||
Baseline CD4 T-cell count | ≤ 200 | 98 (63.6) | 91 (59.1) | 0.413 |
>200 | 56 (36.4) | 63 (40.9) | ||
Current CD4 T-cell count | ≤ 200 | 62 (40.3) | 30 (19.5) | <0.001 |
>200 | 92 (59.7) | 124 (80.5) | ||
Base line Hgb(g/dl) | ≤12 | 51 (33.1) | 43 (27.9) | 0.322 |
>12 | 103 (66.9) | 111 (72.1) | ||
Functional status | Working | 85 (55.2) | 89 (57.8) | 0.295 |
Ambulatory | 64 (41.6) | 55 (35.7) | ||
Bedridden | 5 (3.2) | 10 (6.5) | ||
WHO staging at baseline | stage 1 | 17 (11) | 27 (17.5) | 0.347 |
stage 2 | 57 (37) | 50 (32.5) | ||
stage 3 | 66 (42.9) | 60 (39) | ||
stage 4 | 14 (9.1) | 17 (11) | ||
Treatment staginga | T1 stage | 140 (90.9) | 135 (87.7) | 0.643 |
T2 stage | 10 (6.5) | 13 (8.4) | ||
T3 stage | 4 (2.6) | 6 (3.9) | ||
HIV durationb | <24 months | 7 (4.5) | 7 (4.5) | 0.985 |
24-48 months | 19 (12.3) | 20 (13) | ||
>48 months | 128 (83) | 127 (82.5) | ||
TB before starting ART | Yes | 28 (18.2) | 34 (22) | 0.394 |
No | 126 (81.8) | 120 (78) | ||
TB after starting ART | Yes | 3 (2) | 2 (1.3) | 0.652 |
No | 151 (98) | 152 (98.7) |
Treatment related characteristics of respondents
Variables | Category | Cases(n=154) | Controls (n=154) | p-value for Chi-square test |
---|---|---|---|---|
Frequency (%) | Frequency (%) | |||
Duration on ART | <24 months | 8 (5.2) | 9 (5.8) | 0.781 |
24-48 months | 22 (14.3) | 26 (16.9) | ||
>48 months | 124 (80.5) | 119 (77.3) | ||
Adherence level to ART treatment | Good | 89 (57.8) | 135 (87.7) | <0.001 |
Poor | 65 (42.2) | 19 (12.3) | ||
History of CPT | Yes | 139 (90.3) | 127 (82.5) | 0.046 |
No | 15 (9.7) | 27 (17.5) | ||
History of IPT | Yes | 8 (5.2) | 16 (10.4) | 0.089 |
No | 146 (94.8) | 138 (89.6) | ||
Regimen at the start of ART | d4t+3TC+NVP | 32 (20.8) | 26 (16.9) | 0.931 |
AZT+3TC+NVP | 46 (29.9) | 50 (32.5) | ||
AZT+3TC+EFV | 30 (19.5) | 30 (19.5) | ||
TDF+3TC+EFV | 37 (24) | 38 (24.7) | ||
TDF+3TC+NVP | 9 (5.8) | 10 (6.5) | ||
First line regimen currently | AZT+3TC+NVP | 53 (34.4) | 58 (37.7) | 0.733 |
AZT+3TC+EFV | 32 (20.8) | 31 (20) | ||
TDF+3TC+EFV | 48 (31.2) | 50 (32.5) | ||
TDF+3TC+NVP | 21 (13.6) | 15 (9.8) | ||
Change of ART regimen or individual drug | Yes | 45 (29.2) | 47 (30.7) | 0.803 |
No | 109 (70.8) | 107 (69.5) | ||
History of treatment interruption | Yes | 6 (3.9) | 4 (2.6) | 0.520 |
No | 148 (96.1) | 150 (97.4) |
Predictors of virological treatment failure
Variables | Category | Cases: N (%) | Controls: N (%) | COR(95 %CI) | AOR(95 %CI) | p-value |
---|---|---|---|---|---|---|
Current | ≤ 200 | 62 (40.3) | 30 (19.5) | 2.79(1.67,4.65) |
2.4 (1.35, 4.18)
| 0.003* |
CD4 count (mm3) | >200 | 92 (59.7) | 124 (80.5) | 1 | 1 | |
Current BMI (kg/m2) | <16 | 27 (17.5) | 10 (6.5) | 3.96(1.83,8.58) |
4.2 (1.85,9.51)
| 0.001* |
16-18.5 | 37 (24) | 12 (7.8) | 4.52(2.24,9.14) |
3.7(1.75,7.92)
| 0.001* | |
>18.5 | 90 (58.4) | 132 (85.7) | 1 | 1 | ||
Adherence level to ART | Good | 89 (57.8) | 135 (87.7) | 1 | 1 | <0.0001* |
Poor | 65 (42.2) | 19 (12.3) | 5.2(2.91,9.24) |
5.4 (2.95, 9.97)
|